Drilldown: Medicines

Codeine (2)

Other values:

Search

None (29) · (multiple, generic dominant) (1) · Alfenta (1) · Altace (1) · Darvon (1) · Demerol (1) · Dilaudid (1) · Duragesic (1) · DXM (1) · DXO (1) · Heroin (1) · Krokodil (1) · Lotensin (1) · Nubain (1) · Nucynta (1) · O-DSMT (1) · Opana (1) · Spravato (1) · Stablon (1) · Stadol (1) · Sufenta (1) · Talwin (1) · Ultiva (1) · Vasotec, Vasotec IV, Epaned (1) · Vicodin (1) · Zestril, Prinivil, Qbrelis (1)

Research material · Classic Psychedelic · Stimulant · Opioid · Sedative-Hypnotic · Phenethylamine · Tryptamine · Benzodiazepine · Botanical · [[:Category:Antihypertensives|Antihypertensive]] · Dissociative · Anticonvulsant · Antidepressant · Plant Medicine · Analgesic · Antiparkinsonian · Antipsychotic · Empathogen · Neuroleptic · Cathinone

Other values:

Search

Potent mu-opioid receptor agonist (6) · Mu-opioid receptor agonist (4) · None (3) · NMDA antagonist (3) · NMDA antagonist; sigma receptor agonist (2)

Other values:

Search

None (48) · Mild to moderate pain; cough suppression (low-dose). (1) · Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020). (1) · '"`UNIQ--vote-00000055-QINU`"', '"`UNIQ--vote-00000056-QINU`"', '"`UNIQ--vote-00000057-QINU`"', '"`UNIQ--vote-00000058-QINU`"' (1) · '"`UNIQ--vote-00000A1F-QINU`"', '"`UNIQ--vote-00000A20-QINU`"', '"`UNIQ--vote-00000A21-QINU`"' (1) · '"`UNIQ--vote-00000B81-QINU`"', '"`UNIQ--vote-00000B82-QINU`"', '"`UNIQ--vote-00000B83-QINU`"' (1) · '"`UNIQ--vote-00000C2E-QINU`"', '"`UNIQ--vote-00000C2F-QINU`"', '"`UNIQ--vote-00000C30-QINU`"', '"`UNIQ--vote-00000C31-QINU`"' (1)

None (48) · 10 mg PO once daily (5 mg if on a diuretic); titrate to 40 mg (1) · 2.5 mg PO once daily (1.25 mg in CHF or volume depletion); titrate to 5-10 mg/d (1) · 5-10 mg PO once daily (2.5 mg if on diuretic or in heart failure); titrate to 10-20 mg BID for HFrEF (1) · 5-10 mg PO once daily (2.5 mg in heart failure, hyponatremia, or volume depletion) (1) · Adult: 15–60 mg every 4 hours as needed. (1) · Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site. (1)

None (48) · 1.25, 2.5, 5, 10 mg capsules (1) · 2.5, 5, 10, 20 mg tablets; 1 mg/mL oral solution (Epaned); 1.25 mg/mL IV (enalaprilat) (1) · 2.5, 5, 10, 20, 30, 40 mg tablets; 1 mg/mL oral solution (1) · 28 mg/device (each dose uses 2 devices) (1) · 5, 10, 20, 40 mg tablets (1) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)

None (48) · 20 mg/d (hypertension); 10 mg/d (other indications typical) (1) · 360 mg/day (1) · 40 mg/d (1) · 80 mg/d (2) · 84 mg per session (1)

None (48) · Intranasal (under direct medical supervision) (1) · IV (1) · Oral (4) · PO (only formulation marketed in the US). (1)

None (48) · 30–60 min (PO) (1) · BP effect 1 hour; max at 4-6 hours (1) · BP effect 1-2 hours; max at 6 hours (1) · BP lowering within 1 hour; max at 6 hours (1) · BP lowering within 1 hour; max effect at 6 hours (1) · Within hours of first administration (1)

None (48) · 12-24 hours (1) · 24 hours (3) · 4–6 hours (1) · Acute effect ~24 hours; cumulative effect builds with repeated dosing (1)

None (48) · 10-11 hours (benazeprilat, the active metabolite)'"`UNIQ--ref-00000A22-QINU`"' (1) · 2.5–3 hours (1) · ~11 hours (enalaprilat, the active metabolite)'"`UNIQ--ref-00000B84-QINU`"' (1) · ~12 hours (effective); terminal half-life is biphasic'"`UNIQ--ref-00000059-QINU`"' (1) · ~13-17 hours (ramiprilat, the active metabolite)'"`UNIQ--ref-00000C32-QINU`"' (1) · ~7-12 hours (1)

None (48) · ~25% (oral; food does not affect absorption)'"`UNIQ--ref-0000005A-QINU`"' (1) · ~28% (oral; food slows but does not reduce absorption)'"`UNIQ--ref-00000C33-QINU`"' (1) · ~37% (oral; food does not affect)'"`UNIQ--ref-00000A23-QINU`"' (1) · ~48% intranasal (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1) · ~60% (oral; food does not affect absorption)'"`UNIQ--ref-00000B85-QINU`"' (1)

None (48) · '''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, skull hypoplasia, hypotension. Stop on detection'"`UNIQ--ref-0000005B-QINU`"' (1) · '''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, skull hypoplasia, hypotension. Stop on detection'"`UNIQ--ref-00000A24-QINU`"' (1) · '''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, skull hypoplasia, hypotension. Stop on detection'"`UNIQ--ref-00000B86-QINU`"' (1) · '''Contraindicated in pregnancy''' (all trimesters); fetal renal injury, oligohydramnios, skull hypoplasia, hypotension'"`UNIQ--ref-00000C34-QINU`"' (1) · Avoid; may cause fetal harm (1) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1)

None (48) · Rx, Schedule III (US). REMS program required. (1) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1) · [[USLegal:Prescription only|Rx-only]] in US (4)